The study will assess the safety, pharmacokinetics and efficacy of intra-articularly administered exebacase in patients with chronic PJI of the knee. Credit: Dr. Manuel González Reyes from Pixabay.

Clinical-stage biotechnology firm ContraFect has commenced a Phase Ib/II clinical trial of exebacase in patients with chronic prosthetic joint infections (PJI) of the knee.

The study is being conducted in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with PJI of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will evaluate the safety, pharmacokinetics (PK), and efficacy of intra-articularly administered exebacase in these patients.

The randomised, double-blind and placebo-controlled clinical trial is to be carried out in France.

ContraFect will conduct the study in two parts. The first part will evaluate efficacy at an early and six-week timepoint besides safety and PK.

See Also:

The second part is said to be a long-term clinical safety and efficacy follow-up for up to two years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, the company will randomise the patients into a 3:1 ratio with either exebacase or a placebo in the trial. All patients will receive study drugs in the setting of a DAIR Procedure.

ContraFect president, CEO and chairman Dr Roger Pomerantz said: “This study of exebacase in patients with chronic PJI provides the opportunity to demonstrate clinical efficacy in a new setting and build on the positive data we have seen through compassionate use.

“Currently, prosthetic joint infections are extremely difficult and expensive to treat as antibiotics fail to clear the bacterial biofilms on the prostheses, often resulting in multiple surgeries, or revisions, of the prosthetic implant.

“Patients suffer tremendous loss of mobility and are often immobilized before and during the surgical procedures.”